John Libbey Eurotext

European Journal of Dermatology

MENU

Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? Volume 27, numéro 6, November-December 2017

Illustrations

  • Figure 1
Auteurs
1 Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
2 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, and Center for Rare Immunological and Cardiovascular Diseases, Behçet Center and Lupus Clinic, AOU Careggi, Florence, Italy
3 Nephrology Unit, Parma University Hospital, Parma, Italy
4 Division of Pathology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy

Rituximab is an unconjugated chimaeric monoclonal IgG1κ antibody that binds the transmembrane protein CD20, exclusively expressed by mature B cells. Initially developed for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukaemia, it has also been approved for the treatment of rheumatoid arthritis and for severe forms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, granulomatosis with polyangiitis, and microscopic polyangiitis (MPA) [1]. We report a patient who [...]